Circular 16 of 2025: PUBLICATION OF SUMMARISED PUBLIC ASSESSMENT REPORTS FOR CLINICAL TRIAL APPLICATIONS AND PUBLIC INSPECTION REPORTS FOR GOOD CLINICAL TRIAL PRACTICE (GCP) INSPECTIONS

Circular 15 of 2025-Notification for Publication of Public Inspection Reports

Circular 14 of 2025-DECLARATION REQUIREMENT FOR DIRECTORS AS A CONDITION OF LICENSURE

Circular 13 of 2025-Deposits into MCAZ Bank Accounts

Circular 12 of 2025 – Fees Schedule

CIRCULAR 10 OF 2025-CLASS II RECALL UP TO RETAIL LEVEL OF TORRENT CAPTOPRIL 25MG TABLETS, REG. NO.: 2000/12.3.5/3685, BATCH: B520K001, MANUFACTURED BY TORRENT PHARMACEUTICALS LTD, INDRAD PLANT, NEAR INDRAD VILLAGE, TALUKA KADI, DISTRICT MEHSANA, GUJARAT, INDIA

CIRCULAR 9 of 2025/Publication-Of-Cancelled-Wholesale-Dealer’s-Permits-Pharmacy-Licence-And-Persons’-Licences

Circular 8 of 2025 – Call For Submission of Applications for Registration Of Human Allopathic Medicines Through the Expedited Review Pathway: Phase I of 2025

Circular 7 of 2025 – Call For Submission Of Applications For Registration Through The Expedited Review Pathway For Veterinary Medicinal Products: PHASE I

Circular 6 of 2025_ Clarification on the sale and distribution of unapproved pharmacopeial and galenical preparations

Circular 5 of 2025 – Introduction of Online Payment for MCAZ Online Services.

Circular 3 of 2025 – Alert On Falsified Abhayrab Rabies Vaccine Distributed By Unauthorised Sources

Circular 2 of 2025 – Submission of Annual Returns

Circular 01 of 2025 – Renewal of Cannabis licences

Circular 28 of 2024 – Unapproved Galenical Preparations

Circular 27 of 2024 – Post-Market Surveillance Plan for 2025

Circular 26 0f 2024 – PROCESSING OF APPLICATIONS FOR REGISTRATION OF MEDICINES

Circular No. 25 of 2024 Escalation of Offences Related to the Sale of Unregistered Medicines and Falsification of Medicines

Circular No. 24 of 2024 – MCAZ Annual Shut Down

Circular 23 of 2024 – Class II Recall up to Consumer level of YAZ PLUS Tablets , Reg No. : 2022/21.2.1/6235 , Batch : WEW961J , Manufactured by Bayer (Pvt) Ltd , 27 Wrench Road , Isando 1600, South Africa

Circular 22 of 2024 – Notification of a Class II Recall up to Retail Level of Dextromethorphan/Chlorpheniramine Maleate /Paracetamol/Phenylephrine Hydrochloride 0.SMG/2MG/120MG/2.5MG (4Cs Childrens Cough and Cold Syrup) from Caps (Pvt) Ltd ,2 Manchester Road, Southerton, Harare.

Circular 21 of 2024_Notification for alignment with legal provisions prescribed in the Medicines and Allied Substances Control Regulations when conducting business with the Authority

Circular 20 of 2024_ ERRATUM TO CIRCULAR 19 OF 2024 _ IMPLEMENTATION OF THE MCAZ-SAHPRA MOU IN THE REGISTRATION OF HUMAN ALLOPATHIC MEDICINES

Circular 18 of 2024 – Notification of a Voluntary Class Iii Recall Up To Retail Level Of Paracetamol/ Codeine/ Diphenhydramine/Caffeine (Propain) 400/10/50/5mg Tablets Manufactured by DATLABS, 45 Falcon Street, Belmont, Bulawayo

Circular 17 of 2024 – Implementation of the MCAZ-SAHPRA MOU in the Registration of Human Allopathic Medicines: Phase I

Circular 16 of 2024 – Renewal of Licences for the Production of Cannabis for Medicinal and Scientific Use.

Circular 15 of 2024 – Importation of Unregistered Medicines by Community Pharmacists Under Statutory Instrument 57 of 2008

Circular No 14 of 2024 – Change of MCAZ Banking Details

Circular 13 of 2024 – Invitation to attend an online joint Zimbabwe Anaesthetic Association (ZAA) and MCAZ training on the safe use of Hyperbaric (Heavy) Bupivacaine in Spinal anesthesia, on Saturday 8th of June 2024 from 9am – 12:30pm

Circular 12 of 2024_IMPLEMENTATION PLAN FOR RE-REGISTRATION OF HUMAN ALLOPATHIC MEDICINES RE-REGISTRATION FEES

Circular 11 of 2024-SYSTEM CONFIGURATION TO ZIG

Circular 10 of 2024-Prevention of Diethylene Glycol (DEG) and Ethylene Glycol (EG) Contamination in Pharmaceticals

Circular 9 of 2024 – Wholesale Dealers Permit Renewals

Circular 8 of 2024-Upgrade on the MCAZ Imports/Exports Module

Circular 7 of 2024 – Renewal of Premises Licences for Pharmacies

Circular 6 of 2024 – Notification of the Implemetation Plan for Grouped of Variations and Variation Notification

Circular 5 of 2024 – Publication of Cancelled Wholesale Dealer’s Permits, Pharmacy Licences and Persons’ Licences

Circular 4 of 2024 – Implementation Plan for Re-Registration of Human Allopathic Medicines – Extension of Re-Registration Fee Waiver

Circular 3 of 2024 – Re-Opening of the Cash Receipting Office

Circular 2 of 2024 – Renewal of Licences for the Production of Cannabis for Medicinal and Scientific Use

Circular 1 of 2024 – Submission of Annual Returns

Circular 24 of 2023 :Bulk importation of unregistered medicines

Circular 23 of 2023 – Acquiring Raman Spectroscopy Signatures from Pharmaceutical Wholesalers and Distributors

Circular 27 of 2023 – 2023 Annual Shutdown Notice

Circular 26 of 2023 – Processing of applications for registrations of medicines

Circular 21 of 2023 – Implementation Plan for Re-Registration of Human Allopathic Medicines- Extension of Fees Waiver

Circular 22 of 2023: Publication of Canceled Wholesale Dealer’s Permits, Pharmacy Licences and Person’s Licences

Circular 17 of 2022: CBD Products

Circular 18 of 2023: Fees for Laboratory Analysis Of Complementary Medicines

Circular 19 of 2023: Implementation Plan for Re-Registration of Human Allopathic Medicines _Proposed Fees